CAMBRIDGE, Mass.--(EON: Enhanced Online News)--PixarBio Corporation, (OTCQX: PXRB) developers of NeuroRelease™, a novel morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in late 2018, announced today that our CEO, Frank Reynolds, was named to the 2016 Irish Education 100, a Listing of the Leading Irish-American Figures in Education Across the United States. The exclusive event will be held at the Irish Consulate in NYC by special invitation only on December 7, 2016.
The Irish Education 100 gives tribute to the enduring Irish success in education, especially at the University level. Across the nation, many top institutions have men and women of Irish blood in positions of leadership. The continuing success of Catholic education is a bedrock of American society.
"As Board Member of Chestnut Hill College in Philadelphia, we make decisions that create the innovative classrooms and innovative pathways for students to have a lasting impact on society. It's an honor to be recognized among the 40,000,000 Irish Americans whose ancestors came to America for an opportunity to survive and thrive. Formal education provides the firm bedrock on which a productive life can be lived, and great Universities like Rider University, provided that foundation for me, as I set out to found new companies and invent new drugs, biologics, and medical devices," said PixarBio CEO Frank Reynolds.
The Irish Education 100 honorees are some of the most distinguished and accomplished leaders in America with Irish heritage. It was first compiled by the Irish Voice newspaper in an effort to quantify the Irish commitment to excellence in education in the United States. This year's listing featuring the 2016 Irish Education 100 honorees will appear in a special edition issue of the Irish Voice on December 7, 2016.
The NeuroRelease™ Platform: Non-Addictive and Non-opiate Treatment of
NeuroRelease™ is a morphine replacement, and non-addictive pain platform for the surgical/hospital setting, for the battlefield, or for acute and chronic pain. First product FDA approval for the platform will be for a 14-day post-surgical pain treatment and it is expected in late 2018.
Major Benefits of NeuroRelease™
- Effects only sensory signals
- No effect on locomotion nerve fibers, so patients can enter physical therapy quickly
- Maintains two-point discriminate touch so patients can function
- No effect on proprioception so no effect on a person feeling of well-being
Therefore, patients will maintain two-point discriminate touch, control of their locomotion nerve fibers so they control voluntary movement to enter rehabilitation quickly with a non-addictive morphine replacement. PixarBio’s NeuroRelease™ pain platform also includes 4-8 hour, 3-day, 7-day, 14-day and 90-Day pain treatments all have expected FDA approvals in 2020. NeuroRelease™ is biodegradable, and it's non-toxic so NeuroRelease™ can be re-injected to extend treatment timelines.
PixarBio Corporation was awarded the Boston Business Journal's "2016 Best Places to Work". The award recognizes PixarBio as one of the region's best firms, offering the greatest professional opportunities and work environments to innovate.
About PixarBio Corporation
PixarBio is a public company traded on the OTC markets under the stock symbol PXRB. PixarBio is a specialty pharmaceutical/biotechnology company focused on pre-clinical and clinical commercial development of novel neurological drug delivery systems for post-operative pain. PixarBio researches and develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. Our lead product platform, NeuroRelease™, has achieved sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain in pre-clinical models. For more information, visit www.pixarbio.com.
Safe Harbor Statement
This announcement includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of PixarBio’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of Biotech and medical device industry regulation and health care legislation in the United States and internationally; global trends on cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; PixarBio’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of PixarBio’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
PixarBio Corp undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be obtained through PixarBio’s corporate headquarters at 200 Boston Ave, Suite 1875 in Medford, MA 02155.